Oxygen Biotherapeutics loses $10.3M in fiscal 2013
Morrisville, N.C. —
The Morrisville company narrowed its net loss compared to fiscal 2012, when Oxygen lost $15.7 million. While Oxygen has made progress advancing traumatic brain injury drug candidate Oxycyte through mid-stage clinical trials, it has struggled with the financial ability to support it. The company raised $1.9 million from a February securities offering; enough to start but not finish phase IIb studies on Oxycyte. Oxygen also needed to complete a reverse stock split in May in order to boost the company’s stock price and avoid delisting from the Nasdaq exchange.
Oxygen spent $2.4 million in R&D expenses for the fiscal year, virtually identical to R&D spending in the prior year. But the company closed the fiscal year with less money in the bank. As of April 30, the company had cash and cash equivalents totaling just $783,528 compared with $1.8 million at the end of fiscal 2012.
Please Log In to add a comment.
Best of TechWire Insider
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur